Dr. Fakhoury discusses the use of systemic treatment for patients with severe alopecia areata. He highlights data from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which showed effective results with deuruxilitinib vs placebo in this patient population. Additionally, he emphasizes that the indications for severe alopecia areata have expanded to those with a Severity of Alopecia Tool (SALT) score of 20 to 49 and outlined patient populations who could benefit from treatment with deuruxolitinib.
Podden och tillhörande omslagsbild på den här sidan tillhör
Matrix Medical Communications. Innehållet i podden är skapat av Matrix Medical Communications och inte av,
eller tillsammans med, Poddtoppen.
